Emeren Announces Third Quarter 2024 Financial Results

2024-11-15 Emeren Group Ltd HaiPress

NORWALK,Conn.,Nov. 15,2024 -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL),a leading global solar project developer,owner,and operator,today announced its unaudited financial results for the third quarter ended September 30,2024. Emeren's third quarter 2024 financial results and management commentary can be found by accessing the Company's shareholder letter on the quarterly results page of the Investor Relations section of Emeren Group Ltd's website at https://ir.emeren.com/.

Emeren Group Ltdwill host a conference call today to discuss the results.

Conference Call Details

We will host a conference call today to discuss our third quarter 2024 business and financial results.The call is scheduled to begin at4:30 p.m. U.S. Eastern Time on Thursday,November 14,2024.

Please register in advance to join the conference call using the link provided below and dial in 10 minutes before the call is scheduled to begin. Conference call access information will be provided upon registration.

Participant Online Registration:


https://register.vevent.com/register/BI45573df6da5b45ddbf1d1490be2da2dc

Audio-only Webcast:


https://edge.media-server.com/mmc/p/4s2et8tm

Additionally,an archived webcast of the conference call will be available on the Investor Relations section of Emeren Group Ltd's website at https://ir.emeren.com/.

About Emeren Group Ltd

Emeren Group Ltd (NYSE: SOL),a renewable energy leader,showcases a comprehensive portfolio of solar projects and Independent Power Producer (IPP) assets,complemented by a significant global Battery Energy Storage System (BESS) capacity. Specializing in the entire solar project lifecycle — from development through construction to financing — we excel by leveraging local talent in each market,ensuring our sustainable energy solutions are at the forefront of efficiency and impact. Our commitment to enhancing solar power and energy storage underlines our dedication to innovation,excellence,and environmental responsibility. For more information,go to www.emeren.com.

For investor and media inquiries,please contact:

Emeren Group Ltd - Investor Relations


+1 (925) 425-7335


ir@emeren.com

The Blueshirt Group


Gary Dvorchak


+1 (323) 240-5796


gary@blueshirtgroup.co

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map